High dose-rate tandem and ovoid brachytherapy in cervical cancer: Dosimetric predictors of adverse events

Kara D. Romano, Colin Hill, Daniel M. Trifiletti, M. Sean Peach, Bethany J. Horton, Neil Shah, Dylan Campbell, Bruce Libby, Timothy N. Showalter

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. Methods: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Results: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD2) D2cc was ≥80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD2 D2cc ≥ 65 Gy and seven patients had a sigmoid D2cc ≥ 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Conclusions: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of: less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.

Original languageEnglish (US)
Article number129
JournalRadiation Oncology
Volume13
Issue number1
DOIs
StatePublished - Jul 16 2018

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'High dose-rate tandem and ovoid brachytherapy in cervical cancer: Dosimetric predictors of adverse events'. Together they form a unique fingerprint.

  • Cite this

    Romano, K. D., Hill, C., Trifiletti, D. M., Peach, M. S., Horton, B. J., Shah, N., Campbell, D., Libby, B., & Showalter, T. N. (2018). High dose-rate tandem and ovoid brachytherapy in cervical cancer: Dosimetric predictors of adverse events. Radiation Oncology, 13(1), [129]. https://doi.org/10.1186/s13014-018-1074-2